Industrial Technology Research Institute (ITRI) Coordinated Supramolecular Complex (CSC) for Posterior Eye DeliveryA liquid solution that replaces ocular injections for macular degeneration.
Category: Health, Medical and Biotech
Subcategory: Advanced Drug Delivery
From the winners: “This innovation uses coordinated supramolecular complex (CSC) technology to develop an eye drop formulation for treating wet age-related macular degeneration (AMD). CSC for posterior eye delivery addresses the shortcomings of current treatments, providing a non-invasive and self-administrable alternative for patients.”
“ITRI researchers found that the current administration route for wet AMD treatment is limited to intravitreal injection due to poor bioavailability with other administration routes and that there is no eye drop product for wet AMD on the market. Therefore they developed CSC technology that utilizes a molecular-level delivery carrier with hydrophilic surface to encapsulate both insoluble drug and permeability enhancers. This results in a novel eye drop formulation with improved drug concentration and permeability against ocular tissue, making possible a non-invasive AMD treatment with equal or greater effects to current treatments.”
“ITRI’s eye drop solution is a pioneering formulation that greatly improves drug exposure in posterior ocular tissue for wet AMD treatment. This system enhances drug aqueous solubility and tissue-penetrating capability. Unlike ocular injection treatments currently on the market, ITRI’s innovation eliminates patients’ fear and uncomfortableness of injections directly to their eyeball. It also reduces the side effects such as bleeding, inflammation, retinal detachment, and elevated intraocular pressure, and has shown less systemic exposure than commercial oral tablets.”